We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    pneumagen
Previous Study | Return to List | Next Study

Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05507567
Recruitment Status : Recruiting
First Posted : August 19, 2022
Last Update Posted : January 26, 2023
Sponsor:
Information provided by (Responsible Party):
Pneumagen Ltd.

Brief Summary:
Study to assess the efficacy and safety of a multiple dose regimen and a single dose regimen of intranasal Neumifil, administered prior to challenge with Influenza virus in healthy adult participants

Condition or disease Intervention/treatment Phase
Influenza Viral Infections Drug: Neumifil Drug: Placebo Phase 2

Detailed Description:

This is a single-centre, randomized, double-blind, placebo-controlled study in healthy adult participants to assess the pre-exposure prophylactic antiviral activity of Neumifil via a human viral challenge model.

Participants will enter the quarantine unit on Day -4.

Participants will be randomized to receive either active (single dose), active (multiple dose) or placebo in a 3:3:4 ratio followed by influenza viral challenge on Day 0.

Participants will leave the unit on Day 8, provided that no virus is detected by a qualitative virus antigen test and the participant has no clinically significant symptoms. A final follow-up will be performed on Day 28.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, Double-blind, Placebo-controlled study
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Randomized, Double-blind, Placebo-controlled, Phase 2a Study To Assess the Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza, Via a Human Viral Challenge Model in Healthy Adult Participants
Actual Study Start Date : August 12, 2022
Estimated Primary Completion Date : March 17, 2023
Estimated Study Completion Date : March 17, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot

Arm Intervention/treatment
Experimental: Neumifil multiple dose prophylactic treatment
Neumifil intranasal spray administered as 3 single daily doses prior to viral challenge
Drug: Neumifil
Liquid for intranasal spray administration

Experimental: Neumifil single dose prophylactic treatment
Neumifil intranasal spray administered as a single dose and blinded by placebo administered as two single daily doses. All administrations completed prior to viral challenge
Drug: Neumifil
Liquid for intranasal spray administration

Drug: Placebo
Liquid for intranasal spray administration

Placebo Comparator: Placebo
Intranasal spray administered as 3 single daily doses prior to viral challenge
Drug: Placebo
Liquid for intranasal spray administration




Primary Outcome Measures :
  1. To evaluate the effect of Neumifil in reducing the incidence of symptomatic influenza infection compared to placebo [ Time Frame: Day 1 to Day 8 ]
    Incidence of 2 quantifiable qRT PCR samples on 2 consecutive days AND any symptoms of grade ≥2 at a single time point

  2. To evaluate the effect of Neumifil in reducing the severity of symptoms compared to placebo [ Time Frame: Day 1 to Day 8 ]
    Change in Peak Total Symptom Score as measured by graded symptom scoring system collected 3 times daily; symptom questionnaire will be graded on a scale of 0-3 (grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with me doing my normal daily activities; grade 3: quite bothersome most or all of the time, and it stops me participating in activities).Lower score means better outcome.


Secondary Outcome Measures :
  1. To evaluate the effect of Neumifil in reducing symptoms compared to placebo [ Time Frame: Day 1 to Day 8 ]
    Participants will complete a self-assessment symptom diary card

  2. To evaluate the antiviral effect of Neumifil in reducing or shortening viral shedding when compared to placebo [ Time Frame: Day 1 to Day 8 ]
    Measurement of influenza viral load and duration of quantifiable measurements in nasal samples by qRT-PCR and tissue culture

  3. To evaluate the effect of Neumifil in reducing nasal discharge [ Time Frame: Day 1 to Day 8 ]
    Measurement of total weight of mucus produced and number of tissues used by participants

  4. To evaluate the safety of intranasal doses of Neumifil compared to placebo [ Time Frame: to Day 28 ]
    Occurrence of adverse events, solicited and unsolicited



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Written informed consent signed and dated by the participant and the investigator obtained before any assessment is performed.
  2. Adult male or female aged between 18 and 55 years old, inclusive, on the day prior to signing the consent form.
  3. A total body weight ≥50 kg and body mass index (BMI) ≥18 kg/m2 and ≤35kg/m2.
  4. In good health with no history, or current evidence, of clinically significant medical conditions, and no clinically significant test abnormalities that that will interfere with participant safety, as defined by medical history, physical examination, (including vital signs), ECG, and routine laboratory tests as determined by the investigator.
  5. Participants will have a documented medical history either prior to entering the study or following medical history review with the study physician at screening.
  6. Agree to use highly effective contraception
  7. Serosuitable for the challenge virus

Exclusion Criteria:

  1. History of, or currently active, symptoms or signs suggestive of upper or lower respiratory tract (URT, LRT) infection within 4 weeks prior to the first study visit.
  2. Any history or evidence of any clinically significant or currently active cardiovascular, respiratory, dermatological, gastrointestinal, endocrinological, haematological, hepatic, immunological (including immunosuppression), metabolic, urological, renal, neurological, or psychiatric disease and/or other major disease that, in the opinion of the investigator, may interfere with a participant completing the study and necessary investigations. Includes a history of depression or anxiety.
  3. Any participants who have smoked ≥ 10 pack years at any time.
  4. Females who are pregnant or breastfeeding
  5. Any history of anaphylaxis or history of severe allergic reactions to any foods, drugs, insect bites or stings or any known allergy to tetracycline antibiotics.
  6. Venous access deemed inadequate for the phlebotomy and cannulation demands of the study.
  7. a) Any significant abnormality altering the anatomy of the nose in a substantial way or nasopharynx that may interfere with the aims of the study and, in particular, any of the nasal assessments or viral challenge b) Any evidence of nasal inflammation or nasal polyps within the last month c) Any clinically significant history of epistaxis (large nosebleeds) within the last 3 months of the first study visit and/or history of being hospitalised due to epistaxis on any previous occasion.

    d) Any nasal or sinus surgery within 3 months of the first study visit. Prior or Concomitant Medications and Assessments

  8. a) Evidence of vaccinations within the 4 weeks prior to the planned date of first dosing with IMP.

    b) Intention to receive any vaccination(s) before the last day of follow-up (with the exception of vaccinations recommended for COVID19 as defined by Medicines and Healthcare Regulatory Agency (MHRA)/government vaccination guidelines). No travel restrictions apply after the Day 28 (±3 days) follow-up visit.

    c) Receipt of influenza vaccine (or another IMP relating to treatment of influenza) in the last 6 months prior to the planned date of viral challenge OR a diagnosis of influenza or influenza-like illness confirmed by a physician within the last 2 months prior to screening.

  9. Receipt of blood or blood products, or loss (including blood donations) of 550 mL or more of blood during the 3 months prior to the planned date of first dosing with IMP or planned during the 3 months after the final follow-up visit.
  10. a) Receipt of any investigational drug within 3 months (or 5 half-lives of the IMP used in the other study, whichever is greater), prior to the planned date of first dosing with IMP.

    b) Receipt of 3 or more investigational drugs within the previous 12 months prior to the planned date of first dosing with IMP.

    c) Prior inoculation with a virus from the same virus-family as the challenge virus.

    d) Prior participation in another human viral challenge study with a respiratory virus in the preceding 3 months.

  11. Use or anticipated use during the conduct of the study of concomitant medications
  12. Confirmed positive test for drugs of misuse and cotinine on first study visit

13 Recent history or presence of alcohol addiction, or excessive use of alcohol

14. A FEV1 <80%, a FVC <80% predicted, or an FEV1/FVC ratio <0.7. 15. Positive HIV, hepatitis B virus, or hepatitis C virus test.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05507567


Contacts
Layout table for location contacts
Contact: Douglas Thomson +44 (0) 7748357352 douglas.thomson@pneumagen.com

Locations
Layout table for location information
United Kingdom
hVIVO Services Limited Recruiting
London, United Kingdom, E1 2AX
Contact: Nicolas Noulin       n.noulin@hvivo.com   
Principal Investigator: Melissa Bevan         
Sponsors and Collaborators
Pneumagen Ltd.
Investigators
Layout table for investigator information
Study Director: Geoff Kitson gkitson@propharmapartners.com
Layout table for additonal information
Responsible Party: Pneumagen Ltd.
ClinicalTrials.gov Identifier: NCT05507567    
Other Study ID Numbers: PNG-NMF-201
First Posted: August 19, 2022    Key Record Dates
Last Update Posted: January 26, 2023
Last Verified: January 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pneumagen Ltd.:
Influenza
Human Challenge
Prophylaxis
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Virus Diseases
Respiratory Tract Infections
Infections
Orthomyxoviridae Infections
RNA Virus Infections
Respiratory Tract Diseases